Avedro, a medical device and pharmaceutical company, has raised $43 million in Series D Funding. The round was led by Abingworth and included a significant investment from Third Point Partners. Other investors participating included Prism Venture, De Novo Ventures, Flagship Ventures, Aperture Venture Partners, SCP Vitalife Partners, Borealis Ventures and Echelon Ventures. Based in Waltham, MA, Avedro develops systems and procedures for biomechanically strengthening and modifying the cornea. As part of the transaction, David Mayer from Abingworth and Jason Hong, PhD, from Third Point will join the Board of Directors.